The only genomic test proven to predict a patient’s individual benefit from chemotherapy. For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit.

The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ. For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.

A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures. For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment.